Neon Therapeutics (NASDAQ:NTGN) released its quarterly earnings data on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.01), Bloomberg Earnings reports.
NASDAQ NTGN traded down $0.01 during trading hours on Wednesday, hitting $2.65. The company’s stock had a trading volume of 169,163 shares, compared to its average volume of 163,379. Neon Therapeutics has a 52 week low of $2.43 and a 52 week high of $12.69. The stock has a market capitalization of $75.08 million, a P/E ratio of -0.48 and a beta of 1.62. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.30 and a quick ratio of 7.30. The company’s 50-day moving average price is $3.99.
A number of equities analysts have recently issued reports on the stock. Robert W. Baird assumed coverage on shares of Neon Therapeutics in a research report on Thursday, July 25th. They set an “outperform” rating and a $15.00 price objective on the stock. ValuEngine raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright increased their price objective on shares of Neon Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Morgan Stanley cut their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 16th. Finally, Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Neon Therapeutics has a consensus rating of “Buy” and a consensus target price of $15.13.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Article: Candlestick
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.